NASDAQ:IFRX - Inflarx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inflarx NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.55 -0.20 (-4.21 %) (As of 02/23/2020 04:00 PM ET) Add Compare Today's Range$4.29Now: $4.55▼$4.6850-Day Range$3.21MA: $3.59▼$4.7752-Week Range$2.17Now: $4.55▼$53.10Volume440,731 shsAverage Volume345,335 shsMarket Capitalization$118.12 millionP/E RatioN/ADividend YieldN/ABeta-1.11 ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IFRX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.inflarx.de/ Phone49-36-4150-8180Debt Debt-to-Equity RatioN/A Current Ratio7.81 Quick Ratio7.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.64 per share Price / Book0.60Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-35,210,000.00 Net MarginsN/A Return on Equity-35.75% Return on Assets-32.84%Miscellaneous Employees36 Outstanding Shares25,960,000Market Cap$118.12 million Next Earnings Date3/26/2020 (Estimated) OptionableNot Optionable Receive IFRX News and Ratings via Email Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IFRX Rates by TradingView Inflarx (NASDAQ:IFRX) Frequently Asked Questions What is Inflarx's stock symbol? Inflarx trades on the NASDAQ under the ticker symbol "IFRX." How were Inflarx's earnings last quarter? Inflarx NV (NASDAQ:IFRX) issued its quarterly earnings results on Thursday, August, 9th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.24. View Inflarx's Earnings History. When is Inflarx's next earnings date? Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Inflarx. What price target have analysts set for IFRX? 9 brokers have issued twelve-month target prices for Inflarx's stock. Their forecasts range from $5.00 to $44.00. On average, they expect Inflarx's stock price to reach $12.50 in the next year. This suggests a possible upside of 174.7% from the stock's current price. View Analyst Price Targets for Inflarx. What is the consensus analysts' recommendation for Inflarx? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 2 sell ratings and 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inflarx. Has Inflarx been receiving favorable news coverage? News headlines about IFRX stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inflarx earned a news impact score of -1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Inflarx. Are investors shorting Inflarx? Inflarx saw a drop in short interest in January. As of January 31st, there was short interest totalling 816,000 shares, a drop of 21.5% from the January 15th total of 1,040,000 shares. Based on an average daily volume of 685,500 shares, the short-interest ratio is presently 1.2 days. Approximately 4.5% of the shares of the stock are short sold. View Inflarx's Current Options Chain. Who are some of Inflarx's key competitors? Some companies that are related to Inflarx include Prothena (PRTA), Cue Biopharma (CUE), BioDelivery Sciences International (BDSI), BioSpecifics Technologies (BSTC), Organogenesis (ORGO), Sinovac Biotech (SVA), Beyondspring (BYSI), ProQR Therapeutics (PRQR), Merus (MRUS), Progenics Pharmaceuticals (PGNX), Innate Pharma (IPHYF), Mersana Therapeutics (MRSN), Fulcrum Therapeutics (FULC), OrganiGram (OGI) and AnaptysBio (ANAB). What other stocks do shareholders of Inflarx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inflarx investors own include Global Blood Therapeutics (GBT), AbbVie (ABBV), NovaBay Pharmaceuticals (NBY), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Novavax (NVAX), Sarepta Therapeutics (SRPT) and Pfizer (PFE). Who are Inflarx's key executives? Inflarx's management team includes the folowing people: Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)Mr. Arnd Christ, Chief Financial Officer (Age 53)Mr. Jason M. Marks J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 43)Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy When did Inflarx IPO? (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Inflarx's major shareholders? Inflarx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Ikarian Capital LLC (1.38%), Goldman Sachs Group Inc. (0.64%), Geode Capital Management LLC (0.34%), Oxford Asset Management LLP (0.17%) and Tower Research Capital LLC TRC (0.04%). Which institutional investors are selling Inflarx stock? IFRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Which institutional investors are buying Inflarx stock? IFRX stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Geode Capital Management LLC, Oxford Asset Management LLP and Tower Research Capital LLC TRC . How do I buy shares of Inflarx? Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Inflarx's stock price today? One share of IFRX stock can currently be purchased for approximately $4.55. How big of a company is Inflarx? Inflarx has a market capitalization of $118.12 million. The company earns $-35,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Inflarx employs 36 workers across the globe.View Additional Information About Inflarx. What is Inflarx's official website? The official website for Inflarx is http://www.inflarx.de/. How can I contact Inflarx? Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180. MarketBeat Community Rating for Inflarx (NASDAQ IFRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 178 (Thanks for Voting!)Underperform Votes: 204 (Thanks for Voting!)Total Votes: 382MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?
